icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
n7Sxjpv0P9ZbeB2T